CARLSBAD, Calif., March 7, 2022 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it is now
accepting applications for the Janice Wiesman Young Investigator
Grant Program, which honors Janice
Wiesman, M.D. (1958-2020), a leading global expert on the
neurological impact of amyloidosis. The program awards $50,000 annually for up to two years to
U.S.-based researchers whose work advances the understanding of
transthyretin amyloidosis (ATTR). The deadline for applications is
April 4, 2022.
ATTR amyloidosis is a rare, progressive and fatal disease that
occurs when there is a buildup of abnormal (misfolded)
transthyretin protein in the body's tissues and/or organs. Most
commonly, it affects the peripheral nerves, heart, intestinal
tract, eyes and kidneys.
The inaugural Wiesman grants were presented in 2021 to Trejeeve
Martyn, M.D., an advanced heart failure and transplant cardiology
fellow at Cleveland Clinic, and Jeremy
Slivnick, M.D., an advanced cardiac imaging fellow at the
University of Chicago.
"It was a privilege to know Dr. Wiesman, who dedicated her
career to exploring ways to put an end to this debilitating
disease," said Brett P. Monia, Ph.D., Ionis' chief executive
officer. "We continue to honor her legacy by providing these grants
to drive innovation in the field of transthyretin amyloidosis. As
the first recipients of the inaugural award, we congratulate Dr.
Martyn and Dr. Slivnick and look forward to seeing the results of
their important work to advance amyloidosis disease research,
diagnosis and treatment."
Dr. Martyn's award was granted to support his work on the
development of practical approaches to identify and treat cardiac
amyloidosis. The project leverages electronic health
records to standardize and improve the recognition of and
treatment approach to cardiomyopathy in integrated health
systems.
Dr. Slivnick's award was granted to support his work on the
applications of advanced cardiac imaging in patients with cardiac
amyloidosis. The project focuses on the development and validation
of cardiac imaging-based models to differentiate transthyretin and
immunoglobulin cardiac amyloidosis and to identify cardiac imaging
predictors of thromboembolism in this patient population.
March is Amyloidosis Awareness Month, an opportunity to bring
attention to the seriousness of the disease and the importance of
understanding the symptoms for early diagnosis and treatment.
Eligible investigators can submit applications for the second
round of grants until April 4, 2022.
Details about the program, including eligibility and submission
requirements, can be found here.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in
RNA-targeted therapy, pioneering new markets and changing standards
of care with its novel antisense technology. Ionis currently has
three marketed medicines and a premier late-stage pipeline
highlighted by industry-leading cardiovascular and neurological
franchises. Our scientific innovation began and continues with the
knowledge that sick people depend on us, which fuels our vision of
becoming a leading, fully integrated biotechnology company.
To learn more about Ionis,
visit www.ionispharma.com and follow us on Twitter
@ionispharma.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-calls-for-applications-for-janice-wiesman-young-investigator-grant-program-301496051.html
SOURCE Ionis Pharmaceuticals, Inc.